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Abstract
Purpose Siewert type II esophagogastric junction ade-
nocarcinoma (ADC) and squamous cell carcinoma (SCC)
existing in the same area have distinct clinicopathological
characteristics. The objective of this study was to examine
differences in the surgical treatment and survival data,
according to the histological subtype, in a single high-
volume cancer center.
Methods We retrospectively examined data from a total
of 123 patients. Seventy-two patients with Siewert type II
ADC and 51 patients with SCC in the same area.
Results In terms of the clinicopathological factors, the
SCC patients had more advanced stage disease and thora-
cotomy was more frequently performed than in the ADC
patients. The 5-year overall survival (OS) rates did not
differ significantly between SCC and ADC, regardless of
whether or not mediastinal, splenic hilum and para-aortic
lymph node dissection was performed. Based on the cal-
culated index for the frequency of nodal metastasis and the
five-year OS rate for involvement at each level, only node
nos. 1, 2, 3 and 7 had a high index ([5) in both groups. The
multivariate Cox regression analysis showed that only age
(\65), the pN category and residual tumor classification
were independently associated with the outcome.
Conclusions Differences in the histological type of
esophagogastric junction cancer were not independent
prognostic factors for survival, and there appears to be a
benefit to dissecting the number 1, 2, 3 and 7 lymph nodes.
Keywords Siewert type II  Squamous cell
carcinoma  Surgical treatment
Introduction
In recent years in Western countries, the dominant histo-
logical subtype of carcinoma found in the lower esophagus
and esophagogastric junction (EGJ) has shifted from
squamous cell carcinoma (SCC) to adenocarcinoma (ADC)
[1, 2]. While SCC still accounts for the majority of these
malignancies in Japan, the current availability of Helico-
bacter pylori eradication therapy is anticipated to change
the proportions of these cancers, giving rise to a trend
similar to that observed in Western countries [3].
At the 2nd International Gastric Cancer Congress held in
Munich in 1997, a consensus was reached to classify ADC
in the EGJ into three subtypes according to the Siewert
classification [4]. Using the anatomical classification of the
esophagus, ADC of the EGJ was defined as ADC with
esophageal invasion with the epicenter of a tumor within
5 cm of the EGJ in the TNM Classification of Malignant
Tumors 7th Edition [5] In Japan, Nishi’s classification
system is also used to classify carcinoma of the gastric
cardia, and cancer at the EGJ is defined as a tumor with the
epicenter within 2 cm proximal and distal to the EGJ,
regardless of its histological subtype [6–8].
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As described above, EGJ carcinoma comprises two
histological subtypes, ADC and SCC. ADC and SCC have
distinct predisposing risk factors and clinicopathological
features. However, the carcinoma subtypes were not dis-
tinguished in some of the previous clinical trials, and it is
unclear whether the optimal treatments differ among these
subtypes [9]. For example, the most appropriate surgical
procedures and extents of lymph node dissection for ADC
and SCC [10], considered separately in the ESMO Clinical
Practice Guidelines for the diagnosis, treatment and follow-
up, as well as in the NCCN Clinical Practice Guidelines in
Oncology, have not yet been established. It is of the utmost
importance to investigate the biological characteristics of
ADC and SCC, and to identify the optimal treatment
strategies for these distinct EGJ carcinomas [11].
Type II tumors, carcinomas of the true cardia, with the
epicenter within an area 1 cm above and 2 cm below the
cardia, in particular, are most likely to contain both ADC
and SCC. Histologically specific treatment strategies, like
those used in lung cancer and urinary bladder carcinoma,
may be an important clinical issue, especially for SCC
occurring at the same site as ADC. The objectives of this
study were to examine the differences between SCC and
ADC in terms of the surgical treatment, lymph node
metastasis status and survival data, based on the histological
subtype, in a single Japanese high-volume cancer center.
Methods
We diagnosed type II EGJ carcinoma if the epicenter was
within 1 cm proximal and 2 cm distal to the anatomical
EGJ based on a photograph of the resected specimen [12].
Between January 1985 and December 2008, a total of 6356
patients, 5658 patients with gastric carcinoma and 698 with
esophageal carcinoma, underwent surgery at the Division
of Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
We retrospectively examined the data from a total of 123
of these patients (72 with Siewert type II carcinoma
undergoing at least D1 lymph node dissection and 51
patients with SCC in the same area with the lesion
extending to the esophagus and stomach).
The tumor staging and nodal classification were per-
formed according to the International Union Against
Cancer (UICC) TNM staging system for EGJ cancer [5].
The lymph node levels were numbered according to the
definition established by the Japanese Gastric Cancer
Association and Japanese Esophageal Society [7, 8].
Surgical procedures
In principle, proximal or total gastrectomy without sple-
nectomy via the abdominal approach was carried out for
cT1 carcinoma, and thoracic esophagectomy or total gas-
trectomy with or without splenectomy via the thoracic or
abdominal approach was carried out for cT2–T4 carci-
noma. All procedural decisions were made by the primary
surgeon.
Statistical analysis
Variables were expressed as the mean ± SD. Comparisons
between groups were performed with Student’s t test, the
v2 test and the Mann–Whitney U nonparametric test. The
multivariate analyses using Cox’s proportional hazards
model were performed to identify independent prognostic
factors. The calculated mean survival time (MST) and the
5-year overall survival (OS) rates were calculated from the
initiation of surgery until death. A survival analysis was
performed using the Kaplan–Meier method. The log-rank
test was used to calculate the statistical significance of the
differences in OS rates between groups. A two-tailed value
of p \ 0.05 was considered to indicate a statistically sig-
nificant difference. We evaluated the therapeutic benefit
obtained by node dissection at each lymph node level,
based on the index of the estimated benefit of lymph node
dissection calculated by multiplying the incidence of
metastasis by the 5-year OS rate of patients with metastasis
at each node level [13].
Results
Patient backgrounds and surgical procedures
With regard to the clinicopathological factors, SCC had
more invasive characteristics, including more extensive
esophageal invasion, deeper tumor invasion and more
advanced pathological stages, than ADC. Furthermore, the
intestinal type was more frequently observed in SCC
patients (Table 1).
Thoracic esophagectomy via right thoracotomy or a left
thoracoabdominal (TA) approach was more frequently
performed in SCC patients, whereas total gastrectomy with
caudal pancreatectomy and splenectomy via the abdomi-
nal-transhiatal (TH) approach were the most common
procedures for ADC (Table 1).
Treatment results and survival
The median follow-up was 9.0 years (range 3.8–24.8). The
MST was 48.8 months, and the 5-year OS rate was 45.1 %
for the SCC patients. The corresponding values for the
ADC patients were 60.2 months and 47.2 %. Thus, there
were no significant survival differences between the SCC
and ADC patients (Fig. 1).
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Table 1 Demographics and
surgical procedures of the 123
patients with EGJ carcinoma
(); %
pT pathological depth of tumor
invasion, pT1 invasion of the
mucosa or submucosa, pT2
invasion of the muscularis
propria, pT3 invasion of the
subserosa, pT4 invasion of the
serosa
SCC (51) ADC (72) p value
Tumor size (cm) 5.8 ± 2.0 5.3 ± 2.7 0.2839
Length of esophageal invasion (cm) 3.1 ± 1.8 1.8 ± 1.2 \0.0001
Macroscopic type
Borrmann Type 1, 2 47 (92.2) 42 (58.3)
Borrmann Type 3, 4 4 (7.8) 30 (41.7) \0.0001
Histological type
Differentiated type 37 (72.5) 48 (66.7)
Undifferentiated type 14 (27.5) 24 (33.3) 0.5392
Depth of tumor invasion
pT1/2 6 (11.8) 37 (51.4)
pT3/4 45 (88.2) 35 (48.6) \0.0001
Lymph node metastasis
Negative 17 (33.3) 27 (37.5)
Positive 34 (66.7) 45 (62.5) 0.5546
Peritoneal metastasis
Negative 51 (100) 70 (97.2)
Positive 0 (0.0) 2 (2.8) 0.2462
Liver metastasis
Negative 51 (100) 70 (97.2)
Positive 0 (0.0) 2 (52.8) 0.2462
Venous invasion
Negative 25 (49.0) 29 (40.3)
Positive 26 (51.0) 43 (59.7) 0.2550
Lymphatic invasion
Negative 10 (19.6) 17 (23.6)
Positive 41 (80.4) 55 (76.4) 0.6089
Stage
I/II 18 (35.3) 37 (51.4)
III/IV 33 (64.7) 35 (48.6) 0.0004
Residual tumor
R0 46 (90.2) 67 (93.1)
R1/2 5 (9.8) 5 (6.9) 0.6133
Length of operation (min) 249 ± 63 225 ± 88 0.3470
Blood loss (ml) 216 ± 150 259 ± 217 0.5095
Approaches
Right thoracotomy 11 (21.6) 2 (2.8) \0.0001
Left thoracophrenicolaparotomy 25 (49.0) 20 (27.8) 0.0035
Laparotomy 15 (29.4) 50 (69.4) \0.0001
Combined resection
Spleen 23 (43.1) 42 (58.3) 0.0474
Pancreas 5 (9.8) 21 (29.2) 0.0011
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The 5-year OS rates also did not differ significantly
between SCC and ADC patients with/without dissection of the
lower mediastinal lymph nodes, such as Nos. 108, 110, 111
and 112. There were no differences in the five-year OS rates
between SCC and ADC patients with/without splenic hilum
(No. 10) and para-aortic (No. 16) lymph node dissection.
Distributions of the metastatic nodes and the index
of estimated benefit from lymph node dissection
As shown in Table 2, nodal metastases frequently involved
the abdominal lymph nodes, followed in frequency by node
Nos. 1, 3, 2 and 7 in both ADC and SCC patients. Mediastinal
lymph node dissection was performed in a total of 84 patients,
and the metastatic rate was 22.9 % in SCC patients and
13.9 % in ADC patients. The metastatic rate of the No. 10
lymph node was low, at 0 % in SCC and 7.0 % in ADC
patients. Only 31 patients underwent No. 16 lymph node
dissection, and the metastatic rate was 28.6 % in SCC and
20.8 % in ADC cases (Table 2). Extended lymph node dis-
section was performed for regions where metastasis was
suspected based on the preoperative clinical imaging findings.
p=0.5669ADC 72 60.2 47.2
SCC 51 48.8 45.1
n MST (M) 5YSR (%) p-value






Fig. 1 Overall survival after resection of esophagogastric junction
carcinoma according to histologic subtype
























1 49 20 40.8 27.8 11.3 72 33 45.8 24.2 11.1
2 49 9 18.4 33.3 6.1 72 16 22.2 37.5 8.3
3 49 17 34.7 33.3 11.6 72 29 40.3 27.6 11.1
4s 37 0 0 – 0.0 57 1 1.8 0 0.0
4d 35 0 0 – 0.0 66 2 3.0 50 1.5
5 31 0 0 – 0.0 60 1 1.7 0 0.0
6 36 1 2.8 0 0.0 63 3 4.8 33.3 1.6
7 47 9 19.1 33.3 6.4 71 20 28.2 20 5.6
8a 44 1 2.3 0 0.0 66 5 7.6 20 1.5
9 45 4 8.9 0 0.0 69 11 15.9 9.1 1.4
10 24 0 0 – 0.0 43 3 7.0 33.3 2.3
11p 39 5 12.8 20.0 2.6 64 6 9.4 16.7 1.6
11d 30 0 0 – 0.0 40 0 0 – 0.0
12a 6 1 16.7 0 0.0 36 0 0 – 0.0
16 7 2 28.6 0 0.0 24 5 20.8 20 4.2
a2lat 6 1 16.7 0 0.0 21 5 23.8 20 4.8
a2int 1 1 100 – 0.0 3 1 33.3 0 0.0
b1lat 4 1 25.0 0 0.0 10 1 10.0 0 0.0
b1int 0 0 0 – 0.0 6 0 0 – 0.0
ML 48 15 31.3 9.1 2.1 36 5 13.9 20 2.8
108 21 1 4.8 50.0 2.4 9 0 0 – 0.0
110 46 14 30.4 14.7 4.5 34 4 11.7 25 2.9
111 36 3 8.3 0 0.0 32 0 0 – 0.0
112 12 1 8.3 0 0.0 8 1 12.5 0 0.0
An index of the benefit gained by the dissection of each station was calculated by multiplication of the frequency of metastasis at the station by
the 5-year survival rate of patients with metastasis at that station; metastatic rate 9 5-year OS/100
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Based on the index calculated employing the frequency
of nodal metastasis and the 5-year OS rate for involvement
at each lymph node level, only node Nos. 1, 2, 3 and 7, in
both SCC and ADC patients, had a high index ([5).
Although the estimated therapeutic index of lymph node
dissection was 5 or less, the dissection of No. 110 in SCC
and dissection of No. 16a2 lat in ADC patients were found
to be effective (Table 2).
Lymph node metastasis status, recurrence sites
and the results of the multivariate cox regression
analysis
In 16 patients with mediastinal lymph node metastasis, the
average total number of metastatic lymph nodes was 6.7,
which was significantly higher than that (2.5) in the 68
patients who were positive for metastasis to only the
abdominal lymph nodes. Similar results were obtained
when metastases were examined according to the histo-
logical subtypes of SCC and ADC (Table 3).
Hematogenous metastasis was noted in 25 (10 SCC and
15 ADC) patients, and liver metastasis accounted for 17 of
these patients. Lymphatic metastasis was observed in 14
(11 SCC and 3 ADC) patients; No. 16 lymph node
metastasis in six patients, and mediastinal and cervical
lymph node metastases in three patients each (Table 4).
A multivariate Cox regression analysis showed that only
the age (\65 years), pN category (pN0) and residual tumor
classification (R0) were independently associated with the
outcome. Neither the histological subtype nor lower
mediastinal, No. 10 and 16 node dissections were inde-
pendently associated with the outcomes (Table 5).
Discussion
No standard procedure has yet been established for the
surgical treatment of EGJ carcinoma in terms of the pre-
sence/absence of the need for thoracotomy, extent of
esophageal and gastric resection, extent of mediastinal and
abdominal lymph node dissection and the need for sple-
nectomy. In the present study, we identified clear differ-
ences in the clinicopathological factors, approaches and
surgical procedures used for SCC and ADC in our center.
A Dutch trial involving patients with Siewert type I/II
carcinoma, treated in two high-volume centers, examined
the superiority of two-field lymphadenectomy via the right
TA over D1 lymphadenectomy via the TH approach [14]. It
was recommended that right TA be performed for patients
with type I tumors and TH for those with type II carcinoma
based on a subsequent subset analysis [15].
In Japan, a randomized controlled trial (RCT) was
conducted by the Stomach Cancer Study Group of the
Japan Clinical Oncology Group to compare the left TA
approach with the abdominal-TH approach in patients with
Siewert Type II/III carcinoma (JCOG9502) [16]. The
results failed to demonstrate the superiority of the left TA
approach in terms of the OS. Accordingly, it was con-
cluded that the abdominal-TH approach with para-esoph-
ageal lymph node dissection to a feasible extent should be
recommended for Siewert Type II/III tumors.
Moreover, based on a study involving 1,002 patients,
Siewert et al. [17] justified applying right TA for type I
carcinoma of the esophagus and the abdominal-TH
approach and D2 dissection of abdominal lymph nodes for
type II and III gastric tumors. In addition, Yamashita et al.
Table 3 The total number of cases with lymph node metastasis with







Mediastinal LN metastasis (?) 6.7 ± 5.8 5.3 ± 3.5 9.8 ± 8.8
Mediastinal LN metastasis (-) 2.5 ± 3.6 2.0 ± 3.1 3.0 ± 4.1
p value 0.0003 0.0047 0.0063
Table 4 The number of patients with each site of first recurrence
SCC ADC Total
Hematogenous 10 15 25
Liver 8 9 17
Lung 0 3 3
Bone 2 1 3
Brain 0 1 1
Skin 0 1 1
Lymphatic 11 3 14
Para-aortic 5 1 6
Mediastinal 3 0 3
Cervical 2 1 3
Other abdominal 1 1 2
Peritoneal 1 8 9
Local 1 0 1
Table 5 The results of the multivariate Cox regression analysis for
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[18] examined the optimal extent of lymph node dissection
for Siewert type II carcinoma in a study including 225
patients, and determined that dissection of the paracardial
and lesser curvature nodes is essential for achieving the
therapeutic benefit of surgery. However, all of these studies
were conducted for ADC. Therefore, further studies are
needed to investigate the effects of histological differences
on the distribution of lymph node metastasis and outcomes.
However, to the best of our knowledge, there have been no
reports on the surgical procedures or survival data based on
the tumor histology of EGJ carcinoma.
The survival data in our series included a MST of
60.2 months and a 5-year OS rate of 47.2 % for ADC
patients. The index calculated employing the frequency of
nodal metastasis and the 5-year OS rate for involvement at
each lymph node level indicated that the only lymph nodes
which should be dissected were Nos. 1, 2, 3 and 7 in ADC
patients. The multivariate Cox regression analysis showed
that age, the pN category and the residual tumor classifi-
cation were independently associated with the outcome.
These results are in good agreement with those obtained in
other studies [14, 16–19]. Therefore, the data from our
series are highly consistent with those of previous studies,
indicating the reliability of our present investigation.
In our series, the clinicopathological background factors
and surgical procedures differed between the SCC and
ADC groups, while there were no significant differences in
the outcomes or therapeutic benefits provided by lymph
node dissection. However, only three of the 51 SCC
patients did not undergo mediastinal lymph node dissec-
tion. Because of this possible bias in the data, we cannot
directly assess the clinical significance of mediastinal
lymph node dissection in SCC cases.
The rate of mediastinal lymph node metastasis in our
series was 22.9 % (11/48) in SCC and 13.9 % (5/36) in
ADC patients, which was not significantly different. In
addition, the values of the index of estimated benefit from
the mediastinal lymph node dissection were similar in SCC
and AC cases (2.9–2.2).
In our series of 123 patients, none exhibited mediastinal
lymph nodes metastasis alone, suggesting that metastasis to
mediastinal lymph nodes basically occurs after that to
abdominal lymph nodes. In 16 patients with mediastinal
lymph nodes metastasis, the average total number of met-
astatic lymph nodes was 6.7, which was significantly higher
than that (2.5) in the 68 patients who were positive only for
metastasis to abdominal lymph nodes. Similar results were
obtained when the metastases were examined according to
the histological subtypes. These results indicate that
metastasis of EGJ carcinoma of Siewert type II occurs first
to the abdominal lymph nodes, and then to mediastinal
lymph nodes, regardless of the histopathological subtype of
the tumor. Thus, patients with mediastinal lymph node
metastasis probably already have abdominal lymph node
metastasis, and the total number of metastatic lymph nodes
would inevitably be high. Consequently, the addition of
mediastinal lymph node dissection with additional thora-
cotomy may not provide a meaningful clinical benefit.
Our examination of the recurrence sites revealed that
hematogenous recurrence, mainly in the liver, accounted
for the majority of relapses in both SCC and AC, followed
by No. 16 lymph node recurrence. Only three SCC patients
and none of the ADC patients had mediastinal lymph nodes
recurrence. This revealed hematogenous metastasis to the
liver to be common in EGJ carcinoma cases, an observa-
tion consistent with other studies [18, 20].
Perioperative chemo-radiotherapy for EGJ carcinoma,
including SCC, reportedly improves the outcomes [9].
Since patients with EGJ carcinoma are potentially at high
risk of hematogenous micrometastasis, prophylactic dis-
section of mediastinal lymph nodes would offer no
apparent benefits in terms of the local control or prognostic
improvement. Among our patients with mediastinal lymph
nodes metastasis, one SCC patient with three metastatic
nodes (one at No. 108 and two at No. 110), and only one
ADC patient with one metastatic lymph node, at No. 110,
survived longer than 5 years. Based on these findings, we
speculated that the effectiveness of mediastinal lymph node
dissection is nearly as low in SCC as it is in ADC.
Conclusions
Overall, taking the surgical invasiveness into account, it
can be assumed that the appropriate procedures for both
SCC and ADC include dissection of the abdominal lymph
nodes, focusing on the paracardial area and the lesser
curvature of the stomach, para-esophageal lymph nodes
(No. 110) for SCC, and a part of the para-aortic lymph
nodes (No. 16 a2 lat) for ADE via the abdominal-TH
approach.
A multivariate Cox regression analysis showed that
histological subtype (SCC and ADE) was not an indepen-
dent prognostic factor.
In this study, two datasets for esophageal and gastric
tumors treated in our center were integrated for the ana-
lysis. Thus far, patients with lesions on the esophageal side
have undergone esophageal surgery performed by spe-
cialists, while those with lesions on the gastric side have
been treated by surgeons specializing in gastric surgery.
This historical background may have yielded apparently
contradictory outcomes. Further evidence is needed to
confirm the present findings and establish the outcomes of
each of the skilled approaches used for SCC and ADC.
Such evidence is needed to prepare for the anticipated
increase in the number of patients with EGJ carcinoma.
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